SSG
ACAD icon

Summit Securities Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Summit Securities Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,000
Closed -$427K – 988
2025
Q3 		$427K Buy
+20,000
New +$473K 0.09% 180

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Summit Securities Group's ACAD Position: Q3 2015 in Review

Summit Securities Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2015, closing a stake of 100 shares — an estimated $4K sold.

Summit Securities Group first reported a position in ACAD in Q2 2015 and held it in 1 quarter. The position peaked at $4K in Q2 2015. 187 funds tracked by Wall St. Rank hold ACAD as of Q3 2015.

  • Summit Securities Group reported no remaining Acadia Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Summit Securities Group sold 100 Acadia Pharmaceuticals shares in Q3 2015, an estimated $4K.
  • Summit Securities Group first reported a position in Acadia Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Summit Securities Group's Acadia Pharmaceuticals position peaked at $4K in Q2 2015.
  • 187 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2015.

Based on Summit Securities Group's 13F filing for Q3 2015, filed 12 Nov 2015.